Tumour necrosis factor inhibitors in Crohn's disease and the effect on surgery rates.

ABSTRACT:

Aim

Surgery is an important therapeutic option for Crohn's disease. The need for first bowel surgery seems to have decreased with the introduction of tumour necrosis factor inhibitors (TNFi; adalimumab or infliximab). However, the impact of TNFi on the need for intestinal surgery in Crohn's disease patients irrespective of prior bowel resection is not known. The aim of this work is to compare the incidence of bowel surgery in Crohn's disease patients who remain on TNFi treatment versus those who discontinue it.

Method

We performed a nationwide register-based observational cohort study in Sweden of all incident and prevalent cases of Crohn's disease who started first-line TNFi treatment between 2006 and 2017. Patients were categorized according to TNFi treatment retention les

SUBMITTER: Eberhardson M 

PROVIDER: S-EPMC9306633 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature